
Photo taken from www.yalemedicine.org/specialists/david-braun
Sep 2, 2024, 08:40
David Braun: We can make a personalized vaccine to target those tumor-specific antigens
Dana-Farber Cancer Institute shared a post on X:
“’If we can identify neoantigens specific to a patient’s tumor, we can make a personalized vaccine to target those tumor-specific antigens,’ says David Braun, MD, PhD, a Dana-Farber oncologist leading a trial of a neoantigen-based vaccine for kidney cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 28, 2025, 19:38
Mar 28, 2025, 17:36
Mar 28, 2025, 17:15
Mar 28, 2025, 17:05
Mar 28, 2025, 16:56